drugset / Trial / NCT03089645
MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics and Immunogenicity of Medi5083 alone or in combination with Durvalumab,Tremelimumab, and/or Docetaxel in adult subjects with advanced solid tumors.
Timeline
- Start
- 2017-03-21
- Primary completion
- 2020-06-23
- Completion
- 2020-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | MEDI5083 | Unknown | — | — |
| Subject | Tremelimumab | Monoclonal antibody | — | — |
| Background | Docetaxel | Small molecule | — | — |